While Ironwood Pharmaceuticals Inc has underperformed by -4.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, IRWD fell by -21.11%, with highs and lows ranging from $15.70 to $8.07, whereas the simple moving average fell by -22.42% in the last 200 days.
On January 17, 2024, Craig Hallum started tracking Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) recommending Buy. A report published by Wells Fargo on December 14, 2023, Initiated its previous ‘Overweight’ rating for IRWD. Jefferies also rated IRWD shares as ‘Buy’, setting a target price of $21 on the company’s shares in an initiating report dated November 09, 2023. JMP Securities Initiated an Mkt Outperform rating on September 28, 2023, and assigned a price target of $22. CapitalOne initiated its ‘Overweight’ rating for IRWD, as published in its report on September 02, 2022. Piper Sandler’s report from April 22, 2022 suggests a price prediction of $16 for IRWD shares, giving the stock a ‘Overweight’ rating. Wells Fargo also rated the stock as ‘Equal Weight’.
Analysis of Ironwood Pharmaceuticals Inc (IRWD)
Further, the quarter-over-quarter increase in sales is 9.66%, showing a positive trend in the upcoming months.
One of the most important indicators of Ironwood Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -654.88% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.84, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and IRWD is recording 4.91M average volume. On a monthly basis, the volatility of the stock is set at 4.90%, whereas on a weekly basis, it is put at 3.97%, with a loss of -2.26% over the past seven days. Furthermore, long-term investors anticipate a median target price of $18.00, showing growth from the present price of $8.22, which can serve as yet another indication of whether IRWD is worth investing in or should be passed over.
How Do You Analyze Ironwood Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.15%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 107.14% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
IRWD shares are owned by institutional investors to the tune of 107.14% at present.
